Motivation: Reviewing a patient's home medication list yesterday, I found my favorite offender on the list - aspirin at 325 mg dosage. The man had a drug eluting stent placed two years ago. I grumbled out loud something about unnecessary risks to patients. One of the seniors sitting within earshot struck back that in fact every patient is kept on a full dose aspirin plus clopidogrel after drug eluting stent placement. Turns out that this fact had escaped me nine months into internship. But, is there data to support the practice?
Paper: Mehta, S.R., Tanguay, J.-F., Eikelbloom, J.W., et. al. "Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS7): a randomized factorial trial." Lancet (2010) 376: 1233-43.
Methods: Multinational randomized factorial trial. Inclusion criteria were symptoms of acute coronary syndrome and either EKG evidence or raised biomarkers. All patients underwent coronary angiography with intent to undergo PCI within 72 hours. Exclusion criteria was increased risk of bleeding or active bleeding. All patients initially got full dose aspirin. From day two, patients were randomized to either high dose (300-325 mg) or low dose (75-100 mg) aspirin. In the clopidogrel arm, patients either received 600 mg loading dose followed by 150 mg from days 2-7 or received 300 mg loading dosed followed by 75 mg on days 2-7. With the factorial design, there were four groups receiving varying combinations of clopidogrel and aspirin. Primary outcome was composite of CV death, MI, or stroke within 30 days.
Results:
When the trial was first released, the clopidogrel trial results attracted much attention and controversy. Multiple editorials comment on the analysis of the clopidogrel piece of the trial. I will just describe the aspirin portion of the trial.
Cohort: There were 8624 patients randomized to high dose aspirin and 8639 randomized to low dose aspirin. The two treatment arms were very similar in baseline characteristics. Average age was about 61 years with 25% female. About 63% of the patients had NSTEMI/UA while the remaining patients presented with STEMI. About 37% of patients took regular aspirin, and another 20% took regular clopidogrel prior to randomization.
Angiography: After initial angiography, 8160 of the 8624 (94.6%) in the high dose ASA group received a stent (58% BMS and 42% DES). In the low dose ASA group, 8163 of the 8639 (94.5%) received a stent (58% BMS and 42% DES). Patient did not undergo PCI because of (1) no coronary disease - most common, (2) no suitable area for revascularization, or (3) CABG was better alternative.
Follow-up: Primary outcome of cardiovascular death, stroke, or MI did not differ between the high dose and low dose group (HR: 0.98, 95% CI 0.84-1.13, p = 0.76). Between high and low dose aspirin, there was no difference in definite or probable stent thrombosis (0.9% vs 1.0%, CI: 0.68-1.26). In secondary analysis, recurrent ischemia was slightly higher in low dose aspirin (0.4%) compared to high dose aspirin (0.2%) though event numbers were small to make meaningful post-hoc secondary comparisons. In the overall trial analysis (including those who got PCI and those who did not), high dose aspirin resulted in significant increase in minor bleeding (5.0% vs 4.2%, p = 0.04).
Discussion: This trial shows that even in the acute post-PCI setting, use of a lower dose aspirin does not increase likelihood of stent thrombosis. Some of the strengths of this trial are the randomized trial design with very large number of subjects (over 8,000 in both groups). While this trial looks only at initial 30 day events, low dose aspirin is expected to be adequate in long-term setting as well given its equivalence to high dose aspirin in the high-risk post-procedure period. There are no randomized trials in the long-term setting, but there have been retrospective observational studies which show that there is no increased risk of stent thrombosis with low dose aspirin. On the other hand, there is more definite evidence showing increased risk of bleeding with high dose aspirin compared to low dose aspirin. Current practice guidelines, however, continue to recommend prolonged administration of high dose aspirin after stenting!
Paper: Mehta, S.R., Tanguay, J.-F., Eikelbloom, J.W., et. al. "Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS7): a randomized factorial trial." Lancet (2010) 376: 1233-43.
Methods: Multinational randomized factorial trial. Inclusion criteria were symptoms of acute coronary syndrome and either EKG evidence or raised biomarkers. All patients underwent coronary angiography with intent to undergo PCI within 72 hours. Exclusion criteria was increased risk of bleeding or active bleeding. All patients initially got full dose aspirin. From day two, patients were randomized to either high dose (300-325 mg) or low dose (75-100 mg) aspirin. In the clopidogrel arm, patients either received 600 mg loading dose followed by 150 mg from days 2-7 or received 300 mg loading dosed followed by 75 mg on days 2-7. With the factorial design, there were four groups receiving varying combinations of clopidogrel and aspirin. Primary outcome was composite of CV death, MI, or stroke within 30 days.
Results:
When the trial was first released, the clopidogrel trial results attracted much attention and controversy. Multiple editorials comment on the analysis of the clopidogrel piece of the trial. I will just describe the aspirin portion of the trial.
Cohort: There were 8624 patients randomized to high dose aspirin and 8639 randomized to low dose aspirin. The two treatment arms were very similar in baseline characteristics. Average age was about 61 years with 25% female. About 63% of the patients had NSTEMI/UA while the remaining patients presented with STEMI. About 37% of patients took regular aspirin, and another 20% took regular clopidogrel prior to randomization.
Angiography: After initial angiography, 8160 of the 8624 (94.6%) in the high dose ASA group received a stent (58% BMS and 42% DES). In the low dose ASA group, 8163 of the 8639 (94.5%) received a stent (58% BMS and 42% DES). Patient did not undergo PCI because of (1) no coronary disease - most common, (2) no suitable area for revascularization, or (3) CABG was better alternative.
Follow-up: Primary outcome of cardiovascular death, stroke, or MI did not differ between the high dose and low dose group (HR: 0.98, 95% CI 0.84-1.13, p = 0.76). Between high and low dose aspirin, there was no difference in definite or probable stent thrombosis (0.9% vs 1.0%, CI: 0.68-1.26). In secondary analysis, recurrent ischemia was slightly higher in low dose aspirin (0.4%) compared to high dose aspirin (0.2%) though event numbers were small to make meaningful post-hoc secondary comparisons. In the overall trial analysis (including those who got PCI and those who did not), high dose aspirin resulted in significant increase in minor bleeding (5.0% vs 4.2%, p = 0.04).
Discussion: This trial shows that even in the acute post-PCI setting, use of a lower dose aspirin does not increase likelihood of stent thrombosis. Some of the strengths of this trial are the randomized trial design with very large number of subjects (over 8,000 in both groups). While this trial looks only at initial 30 day events, low dose aspirin is expected to be adequate in long-term setting as well given its equivalence to high dose aspirin in the high-risk post-procedure period. There are no randomized trials in the long-term setting, but there have been retrospective observational studies which show that there is no increased risk of stent thrombosis with low dose aspirin. On the other hand, there is more definite evidence showing increased risk of bleeding with high dose aspirin compared to low dose aspirin. Current practice guidelines, however, continue to recommend prolonged administration of high dose aspirin after stenting!
There is also no evidence that 325mg works better for secondary prevention of ischemic stroke. But its human nature to think that "more is better."
ReplyDeleteMy husband was diagnosed with early onset Parkinson's disease at 57.his symptoms were shuffling of feet,slurred speech, low volume speech, degradation of hand writing, horrible driving skills, right arm held at 45 degree angle, things were tough for me, but now he finally free from the disease with the help of total cure ultimate health home, he now walks properly and all symptoms has reversed, he had trouble with balance especially at night, getting into the shower and exiting it is difficult,getting into bed is also another thing he finds impossible.we had to find a better solution for his condition which has really helped him a lot,the biggest helped we had was ultimatehealthhome they walked us through the proper steps,am highly recommended this ultimatehealthhome@gmail.com to anyone who needs help.
ReplyDelete